Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Halpin

Showing results (141-150 of 197) with videos related to

Pageof 20
Sort By:
Advances in Therapy|July 20, 2022
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.
Advances in Therapy|July 18, 2022
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.
BMJ Open Respiratory Research|May 21, 2024
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort studyKieran J Rothnie, Robert P Wood, Alexandrosz Czira, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 24, 2022
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?K Mortimer, M Montes de Oca, S Salvi, et al.
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Respiratory Medicine|September 10, 2022
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baselineArnaud Bourdin, J Christian Virchow, Alberto Papi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.
Pageof 20

Showing results (141-150 of 197) with videos related to

Sort By:
Pageof 20
Advances in Therapy|July 20, 2022
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.
Advances in Therapy|July 18, 2022
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.
BMJ Open Respiratory Research|May 21, 2024
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort studyKieran J Rothnie, Robert P Wood, Alexandrosz Czira, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 24, 2022
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?K Mortimer, M Montes de Oca, S Salvi, et al.
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Respiratory Medicine|September 10, 2022
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baselineArnaud Bourdin, J Christian Virchow, Alberto Papi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.
Pageof 20